Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study
Candelaria, Myrna, González, Derlis E., Delamain, Marcia Torresan, Bär, Daniel Oscar, Beniwal, Surender Kumar, Dasappa, Lokanatha, Flores, David Hugo, Querol, John, Guan, Toh See, Lipatov, Oleg Nikolaevich, Volodicheva, Elena Mikhailovna, Patel, Moosa, Safaee Nodehi, Sayyed Reza, Fogliatto, Laura, Paravisini, Alexandra, Perez Diaz, Luis
Published in Leukemia & lymphoma (06.12.2019)
Published in Leukemia & lymphoma (06.12.2019)
Get full text
Journal Article
A Randomized, Double-Blind, Phase III Study Comparing Proposed Biosimilar Rituximab (RTXM83) Versus Reference Rituximab, Both in Combination with CHOP, in the First Line Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
Candelaria, Myrna, Gonzalez, Derlis Emilio, Beniwal, Surender Kumar, Dasappa, Lokanatha, Bar, Daniel Oscar, Delamain, Marcia Torresan, Mukhopadhyay, Ashis, Flores, David Hugo, Bhurani, Dinesh, Radhakrishnan, Venkatraman, Salvatierra, Alejandro, Kowalyszyn, Ruben Dario, Lipatov, Oleg, Patel, Moosa, Schusterschitz, Sergio, Volodicheva, Elena, Perez, Luis Antonio
Published in Blood (08.12.2017)
Published in Blood (08.12.2017)
Get full text
Journal Article